Phase II single-arm, multi-center trial of BGB-A317 patients with previously treated, PD-L1-positive, locally advanced or metastatic urothelial cancer (UC).
Phase of Trial: Phase II
Latest Information Update: 28 Feb 2018
At a glance
- Drugs Tislelizumab (Primary)
- Indications Urogenital cancer
- Focus Registrational; Therapeutic Use
- Sponsors BeiGene
- 28 Feb 2018 According to a BeiGene media release, enrollment completion is expected in 2018.
- 07 Jul 2017 New trial record
- 05 Jul 2017 According to a BeiGene media release, Professor Dingwei Ye of the Fudan University Shanghai Cancer Center is the lead principal investigator of this trial.